NICE EXPANDS GUIDANCE FOR LOKELMA®▼(sodium zirconium cyclosilicate) IN ADULT PATIENTS WITH PERSISTENT HYPERKALAEMIA People living with persistent hyperkalaemia in England, Wales and Northern Ireland will now be able to access repeat prescriptions of sodium zirconium cyclosilicate (SZC) in the community.[1]T.
Osimertinib will be made available via the Cancer Drugs Fund (CDF) to patients in England with completely resected early-stage IB-IIIA EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).1
AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO - (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
1
AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
Patients with early-stage lung cancer are treated with the intention of cure; however, many relapse because treatment is limited to surgery and adjuvant chemotherapy.
2
Unprecedented clinical trial data show that osimertinib, the first approved targeted oral therapy in this setting, can reduce the risk of disease recurrence or death by 80% in patients with early-stage (IB-IIIA) EGFR mutation-positive NSCLC versus placebo.